JP2019527229A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527229A5
JP2019527229A5 JP2019504021A JP2019504021A JP2019527229A5 JP 2019527229 A5 JP2019527229 A5 JP 2019527229A5 JP 2019504021 A JP2019504021 A JP 2019504021A JP 2019504021 A JP2019504021 A JP 2019504021A JP 2019527229 A5 JP2019527229 A5 JP 2019527229A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
acid sequence
protein
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019504021A
Other languages
English (en)
Japanese (ja)
Other versions
JP7556688B2 (ja
JP2019527229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044321 external-priority patent/WO2018022967A1/en
Publication of JP2019527229A publication Critical patent/JP2019527229A/ja
Publication of JP2019527229A5 publication Critical patent/JP2019527229A5/ja
Priority to JP2023019464A priority Critical patent/JP2023071704A/ja
Application granted granted Critical
Publication of JP7556688B2 publication Critical patent/JP7556688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019504021A 2016-07-28 2017-07-28 Gpr156変異体及びその使用 Active JP7556688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023019464A JP2023071704A (ja) 2016-07-28 2023-02-10 Gpr156変異体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
US62/367,973 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023019464A Division JP2023071704A (ja) 2016-07-28 2023-02-10 Gpr156変異体及びその使用

Publications (3)

Publication Number Publication Date
JP2019527229A JP2019527229A (ja) 2019-09-26
JP2019527229A5 true JP2019527229A5 (cg-RX-API-DMAC7.html) 2020-09-03
JP7556688B2 JP7556688B2 (ja) 2024-09-26

Family

ID=59649989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019504021A Active JP7556688B2 (ja) 2016-07-28 2017-07-28 Gpr156変異体及びその使用
JP2023019464A Pending JP2023071704A (ja) 2016-07-28 2023-02-10 Gpr156変異体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023019464A Pending JP2023071704A (ja) 2016-07-28 2023-02-10 Gpr156変異体及びその使用

Country Status (13)

Country Link
US (4) US10266582B2 (cg-RX-API-DMAC7.html)
EP (2) EP4230648A3 (cg-RX-API-DMAC7.html)
JP (2) JP7556688B2 (cg-RX-API-DMAC7.html)
KR (2) KR102661616B1 (cg-RX-API-DMAC7.html)
CN (1) CN109563516B (cg-RX-API-DMAC7.html)
AU (1) AU2017302611B2 (cg-RX-API-DMAC7.html)
CA (1) CA3032124A1 (cg-RX-API-DMAC7.html)
DK (1) DK3491014T5 (cg-RX-API-DMAC7.html)
IL (1) IL264473A (cg-RX-API-DMAC7.html)
MX (2) MX2019001084A (cg-RX-API-DMAC7.html)
NZ (1) NZ751010A (cg-RX-API-DMAC7.html)
SG (1) SG11201900738YA (cg-RX-API-DMAC7.html)
WO (1) WO2018022967A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900738YA (en) * 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof
CN111373053B (zh) 2017-09-06 2024-07-30 雷杰纳荣制药公司 单免疫球蛋白白介素-1受体相关分子(sigirr)变体及其用途
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
SG11202106423PA (en) * 2019-01-17 2021-07-29 Regeneron Pharma A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
WO1996005298A1 (en) 1994-08-09 1996-02-22 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il-8和il-8受体的反义寡核苷酸抑制肿瘤生长
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2001079230A2 (en) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
CN104583402A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
US20200276110A1 (en) * 2015-12-21 2020-09-03 Bayer Oy A method of manufacturing a vaginal ring
SG11201900738YA (en) 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof

Similar Documents

Publication Publication Date Title
Kammerer et al. Heterodimerization of a functional GABAB receptor is mediated by parallel coiled-coil α-helices
JP6559227B2 (ja) 細胞透過性の改善のための進化型巨大分子伝達ドメイン(advanced macromolecule transduction domain)(AMTD)配列、それをコードするポリヌクレオチド、それを含むAMTDの固有の特性を同定する方法、それを含むAMTD配列を開発する方法
JP2010110330A5 (cg-RX-API-DMAC7.html)
JP2011501942A5 (cg-RX-API-DMAC7.html)
Generous et al. Identification of putative interactions between swine and human influenza A virus nucleoprotein and human host proteins
JP2005507648A5 (cg-RX-API-DMAC7.html)
CN101440128A (zh) 人脑胶质瘤中差异表达的蛋白及其用途
JP2013502217A5 (cg-RX-API-DMAC7.html)
JP2008517918A5 (cg-RX-API-DMAC7.html)
CN103954601A (zh) 一种mdm2拮抗剂的检验试剂盒及其制备方法
JP2008509659A5 (cg-RX-API-DMAC7.html)
US9085641B2 (en) Peptides regulating the surface expression of the T cell receptor
To Interaction Study of Influenza RNA Polymerase Subunit PB2 and Nucleoprotein
CN102329377B (zh) 狂犬病病毒优势表位肽抗原及其用途
JP2013545440A (ja) マカカ・ファシキュラリス(Macacafascicularis)CCL17
JP7709383B2 (ja) 抗体の精製を促進するための機能化ubxタンパク質物質
RU2020112313A (ru) Варианты члена 1 семейства 14 переносчиков растворенных веществ (slc14a1)и их применение
IL272940B1 (en) Variants linked to the interleukin-1 immunoglobulin-single receptor and their uses
WO2001048221A1 (fr) Nouveau polypeptide, colipase 12, et polynucleotide codant pour ce polypeptide
WO2001085752A1 (fr) Polynucleotide codant un peptide de myosine
WO2001083743A1 (fr) Polypeptide sous-unite 11 d'adducine alpha de globule rouge humain et polynucleotide codant pour ce polypeptide
WO2001055197A1 (fr) Nouveau polypeptide, facteur humain de liberation de la corticotropine 23(hcrf-23), et polynucleotide codant pour ce polypeptide
JP2005500820A5 (cg-RX-API-DMAC7.html)
WO2001077162A1 (fr) Nouveau polypeptide, sous-unite humaine 12 de sodium, et polynucleotide codant pour ce polypeptide
WO2001055374A1 (fr) Nouveau polypeptide, sequence 71 de multirepetition de la leucine, et polynucleotide codant pour ce polypeptide